Steve Barash

614 total citations
25 papers, 298 citations indexed

About

Steve Barash is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Steve Barash has authored 25 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 7 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Steve Barash's work include Migraine and Headache Studies (14 papers), Trigeminal Neuralgia and Treatments (7 papers) and Neutropenia and Cancer Infections (5 papers). Steve Barash is often cited by papers focused on Migraine and Headache Studies (14 papers), Trigeminal Neuralgia and Treatments (7 papers) and Neutropenia and Cancer Infections (5 papers). Steve Barash collaborates with scholars based in United States, Israel and Germany. Steve Barash's co-authors include Wei Wang, Yanggu Shi, Joshua M. Cohen, Xiaoping Ning, Noa Avisar, Oleg Gladkov, Igor Bondarenko, Maja Galić, Holly Soares and Iris Grossman and has published in prestigious journals such as New England Journal of Medicine, Blood and Neurology.

In The Last Decade

Steve Barash

24 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steve Barash United States	9	116	87	57	54	47	25	298
S Vlaho Germany	10	200 1.7×	124 1.4×	40 0.7×	91 1.7×	41 0.9×	24	513
Esther Ganelin‐Cohen Israel	10	106 0.9×	31 0.4×	49 0.9×	38 0.7×	14 0.3×	26	274
Toshiro Maihara Japan	11	179 1.5×	74 0.9×	97 1.7×	116 2.1×	14 0.3×	33	396
Péter Körtvelyessy Germany	10	77 0.7×	47 0.5×	25 0.4×	41 0.8×	59 1.3×	19	312
Ewa Jamroz Poland	13	241 2.1×	47 0.5×	139 2.4×	50 0.9×	9 0.2×	52	529
Itxaso Martì Spain	8	125 1.1×	35 0.4×	83 1.5×	68 1.3×	27 0.6×	20	534
TJ O'Brien United States	7	249 2.1×	38 0.4×	31 0.5×	152 2.8×	25 0.5×	12	528
Silvia Vieker Germany	6	86 0.7×	104 1.2×	40 0.7×	76 1.4×	25 0.5×	13	313
Jeremy Williams United States	12	184 1.6×	19 0.2×	25 0.4×	20 0.4×	43 0.9×	15	363
Thea Giacomini Italy	9	75 0.6×	46 0.5×	74 1.3×	25 0.5×	8 0.2×	32	222

Countries citing papers authored by Steve Barash

Since Specialization

Citations

This map shows the geographic impact of Steve Barash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Barash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Barash more than expected).

Fields of papers citing papers by Steve Barash

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Barash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Barash. The network helps show where Steve Barash may publish in the future.

Co-authorship network of co-authors of Steve Barash

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Barash. A scholar is included among the top collaborators of Steve Barash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Barash. Steve Barash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hershey, Andrew D., et al.. (2026). Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine. 394(3). 243–252.

Frank, Samuel, Jody Goldstein, Elise Kayson, et al.. (2025). Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. CNS Drugs. 39(2). 185–195. 1 indexed citations

Hershey, Andrew D., Christina L. Szperka, Piero Barbanti, et al.. (2025). Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (PL5.001). Neurology. 104(7_Supplement_1). 1 indexed citations

Frank, Samuel, Karen E. Anderson, Hubert H. Fernandez, et al.. (2024). Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. Neurology and Therapy. 13(3). 655–675. 3 indexed citations

Kahan, Natan R., et al.. (2024). A Prospective, Observational Study to Evaluate the Long-term Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (P8-12.007). Neurology. 102(17_supplement_1). 1 indexed citations

Hellriegel, Edward T., Hang Zeng, Xiaofeng Lu, et al.. (2024). Measurement and Modeling of Peripherally Administered Anti-CGRP Monoclonal Antibody in CSF and Brain of Healthy Volunteers (S22.006). Neurology. 102(7_supplement_1). 2 indexed citations

Saigoh, Kazumasa, Takao Takeshima, Masami Nakai, et al.. (2023). Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials. Journal of Pain Research. Volume 16. 1311–1319. 1 indexed citations

Saigoh, Kazumasa, Takao Takeshima, Masami Nakai, et al.. (2023). Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials. Journal of Pain Research. Volume 16. 1673–1682. 3 indexed citations

Ashina, Messoud, et al.. (2023). Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis. Headache The Journal of Head and Face Pain. 63(10). 1351–1358. 1 indexed citations

10.

McAllister, Peter, et al.. (2022). Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. The Journal of Headache and Pain. 23(1). 112–112. 8 indexed citations

11.

MaassenVanDenBrink, Antoinette, Gisela M. Terwindt, Joshua M. Cohen, et al.. (2021). Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. The Journal of Headache and Pain. 22(1). 152–152. 11 indexed citations

12.

Ashina, Messoud, Joshua M. Cohen, Maja Galić, et al.. (2021). Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. The Journal of Headache and Pain. 22(1). 68–68. 26 indexed citations

13.

Spierings, Egilius L.H., et al.. (2021). A Phase 2 Study of Fremanezumab as a Treatment for Posttraumatic Headache in Adult Patients (1588). Neurology. 96(15_supplement). 10 indexed citations

14.

Barash, Steve, et al.. (2021). Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020. Naunyn-Schmiedeberg s Archives of Pharmacology. 394(11). 2343–2346. 1 indexed citations

15.

Spierings, Egilius L.H., et al.. (2021). Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study. Headache The Journal of Head and Face Pain. 61(9). 1376–1386. 18 indexed citations

16.

Zou, Linglong, et al.. (2018). Immunogenicity Assessment of Tbo-Filgrastim in Cancer Patients Receiving Chemotherapy. Bioanalysis. 10(15). 1221–1228. 1 indexed citations

17.

Barash, Steve, et al.. (2017). Evaluation of a Biologic Formulation Using Customized Design of Experiment and Novel Multidimensional Robustness Diagrams. Journal of Pharmaceutical Sciences. 107(3). 797–806. 5 indexed citations

18.

Geva, Michal, Rebecca Kusko, Holly Soares, et al.. (2016). Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Human Molecular Genetics. 25(18). 3975–3987. 65 indexed citations

19.

Avisar, Noa, et al.. (2015). First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Cancer Chemotherapy and Pharmacology. 75(5). 929–939. 4 indexed citations

20.

Volovăț, Constantin, Oleg Gladkov, Igor Bondarenko, et al.. (2013). Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. Clinical Breast Cancer. 14(2). 101–108. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact